Physician profile
Ivan Colon
NPI 1366446825
$15,238.30
in general payments reported to CMS, 2019-2025
24 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,977 · 2020: $3,566 · 2021: $1,677 · 2022: $4,754 · 2023: $380 · 2024: $207 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,580.52 | 2019-2022 | |
| Acerus Pharmaceuticals Corporation | $4,574.74 | 2020-2022 | |
| Astellas Pharma US INC | $1,350.48 | 2019-2024 | Myrbetriq, Veozah |
| Axonics, INC. | $1,117.11 | 2020-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $749.13 | 2019-2025 | Spaceoar Vue System - 10ml, Ams 700, Rezum Generator |
| Neotract INC. | $457.66 | 2020 | |
| Teleflex LLC | $340.84 | 2021-2025 | Barrigel |
| Coloplast Corp | $214.99 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $168.38 | 2021-2023 | Prolaris |
| Janssen Biotech, INC. | $111.24 | 2019-2024 | Akeega, Erleada |
| Aytu Biopharma, INC. | $105.28 | 2019-2020 | |
| Palette Life Sciences, INC. | $86.83 | 2022-2023 | |
| Foundation Medicine, INC. | $58.83 | 2020-2021 | |
| Olympus America INC. | $56.03 | 2025 | Itind System |
| Smith+Nephew, INC. | $48.70 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $37.41 | 2021-2023 | Trelstar |
| Blue Earth Diagnostics | $29.74 | 2021-2022 | |
| Abbvie INC. | $27.91 | 2023 | Vraylar |
| Dentsply Ih Ab | $25.90 | 2024 | Lofric |
| Progenics Pharmaceuticals, INC. | $24.95 | 2024 | |
| Urogen Pharma, INC. | $20.58 | 2023 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $20.10 | 2019 | |
| 180 Medical, INC. | $17.31 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Colon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.